Vetenskaplig data

FÖRFATTARE TITEL DATUM ÄMNE
Esser S et al. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts 17 Nov 2023 RWD OF BVY
Ogbuagu O et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial Augusti 2023 LENACAPAVIR STUDY
Sax PE et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials Maj 2023 BVY TREATMENT DURING 5Y
Maggiolo F et al. Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide 3 Nov 2022 RWD FORGIVENESS OF BVY
Segal-Maurer S et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Maj 2022 LENACAPAVIR STUDY
Jespersen NA et al. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era Juli 2021 BURDEN OF COMORBIDTIES IN PWH
Gaur AH et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial 21 Juli 2021 CHILDREN AND ADOLESCENT DATA BVY
Maggiolo F et al. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial 9 Mars 2021 AGED ≥ 65 DATA BVY
Daar ES et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial Juli 2018 SWITCH REGISTRATIONAL TRIAL BVY
Molina JM et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial 17 Juni 2018 SWITCH REGISTRATIONAL TRIAL BVY
Gallant J et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Nov 2017 NAIVE REGISTRATIONAL TRIAL BVY
Sax PE et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Aug 2017 NAIVE REGISTRATIONAL TRIAL BVY
Kontakta oss

Kontakta våra sälj- och medicinska team

Har du frågor om våra läkemedel eller produkter? Kontakta oss.

Kontakta oss Kontakta våra medicinska team

SE-COR-0031, March 2026